Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Follistatin 344 vs Lonapegsomatropin (Skytrofa)
An educational, source-based comparison of Follistatin 344 and Lonapegsomatropin (Skytrofa) — how each peptide works, what it's researched for, and what to know before going deeper.
Myostatin-binding protein fragment researched for muscle growth.
A naturally occurring glycoprotein that binds and neutralizes myostatin and activin, releasing the natural brake on skeletal muscle growth in preclinical models.
- Muscular dystrophy models
- Skeletal muscle hypertrophy
- Age-related sarcopenia (preclinical)
- • Off-target effects on activin signaling (reproductive, cardiac) are a concern.
- • Not FDA-approved; banned by WADA.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Follistatin 344 | Follistatin gene delivery enhances muscle growth and strength | Science Translational Medicine | 2009 | Demonstrated durable hypertrophy in primate models. |
| Lonapegsomatropin (Skytrofa) | heiGHt trial | JCEM | 2021 | Non-inferior annualized height velocity vs daily somatropin. |
Side-effect & safety grid
- Off-target effects on activin signaling (reproductive, cardiac) are a concern.
- Not FDA-approved; banned by WADA.
- FDA-approved.
- Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Follistatin 344 vs Lonapegsomatropin (Skytrofa) — Key differences
- Class: Follistatin 344 is classified as Muscle · Myostatin Inhibition, while Lonapegsomatropin (Skytrofa) is GH Analog · Endocrine.
- Primary research focus: Follistatin 344 — muscular dystrophy models; Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency.
- Tag: Muscle vs FDA-Approved · Endocrine.